Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Lanillos

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
NPJ Genomic Medicine|February 19, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing dataJavier Lanillos, Marta Carcajona, Paolo Maietta, et al.
European Urology|June 10, 2022
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell CarcinomaJavier Lanillos, María Santos, Carlos Valdivia, et al.
Orphanet Journal of Rare Diseases|March 1, 2022
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patientsLaura Pena-Couso, María Ercibengoa, Fátima Mercadillo, et al.
Journal of Clinical Medicine|July 8, 2020
A Novel Approach for the Identification of Pharmacogenetic Variants in <i>MT-RNR1</i> through Next-Generation Sequencing Off-Target DataJavier Lanillos, María Santos, Marta Carcajona, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 14, 2021
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinomaMaría Santos, Javier Lanillos, Juan María Roldan-Romero, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
American Journal of Cancer Research|June 9, 2023
María Santos, Javier Lanillos, Eduardo Caleiras, et al.
International Journal of Cancer|June 1, 2023
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibitionJuan M Roldán-Romero, Carlos Valdivia, Maria Santos, et al.
Cancers|November 13, 2020
Novel <i>DNMT3A</i> Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid CarcinomaSara Mellid, Javier Coloma, Bruna Calsina, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2020
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcomeJuan María Roldan-Romero, María Santos, Javier Lanillos, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
NPJ Genomic Medicine|February 19, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing dataJavier Lanillos, Marta Carcajona, Paolo Maietta, et al.
European Urology|June 10, 2022
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell CarcinomaJavier Lanillos, María Santos, Carlos Valdivia, et al.
Orphanet Journal of Rare Diseases|March 1, 2022
Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patientsLaura Pena-Couso, María Ercibengoa, Fátima Mercadillo, et al.
Journal of Clinical Medicine|July 8, 2020
A Novel Approach for the Identification of Pharmacogenetic Variants in <i>MT-RNR1</i> through Next-Generation Sequencing Off-Target DataJavier Lanillos, María Santos, Marta Carcajona, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 14, 2021
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinomaMaría Santos, Javier Lanillos, Juan María Roldan-Romero, et al.
The Oncologist|June 30, 2021
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 TrialEnrique Grande, Cristina Rodriguez-Antona, Carlos López, et al.
American Journal of Cancer Research|June 9, 2023
María Santos, Javier Lanillos, Eduardo Caleiras, et al.
International Journal of Cancer|June 1, 2023
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibitionJuan M Roldán-Romero, Carlos Valdivia, Maria Santos, et al.
Cancers|November 13, 2020
Novel <i>DNMT3A</i> Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid CarcinomaSara Mellid, Javier Coloma, Bruna Calsina, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2020
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcomeJuan María Roldan-Romero, María Santos, Javier Lanillos, et al.
Pageof 2